Near-infrared fluorescence imaging for intraoperative visualization of tumors by surgeons, leading to radical resection of tumor tissue
SurgiMAb’s innovative fluorescent conjugates allow surgeons to get a clear-cut image of tumors in real-time so that they can perform more radical surgery.
Intraoperative fluorescence guidance will help decrease both under- and over-treatment by providing oncologic surgeons with a clear delineation of tumors within a healthy environment.
SurgiMab’s lead molecule specifically targets various digestive tumors such as colon, rectum or pancreas tumors. Surgical navigation then allows tumors to be displayed intra-operatively, allowing complete resection. In case of recurrent cancer, when fibrotic tissue sometimes impairs the surgeon’s vision, it can also help the surgeon preserve important structures.
Intraoperative tumor imaging with SurgiMab’s targeted molecules represents a real-time improvement in the intraoperative differentiation between normal and cancer tissue. It will participate in the new paradigm-shift in cancer surgery: surgeons will improve patient outcome while lowering health-care costs.
Turn a hidden threat into
a visible target
SurgiMab’s technology is based on tumor-specific antibodies conjugated to a near-infra-red fluorescent dye. This injectable dye has been optimized for the fluorescence-guided-surgery of small-size tumor nodules.
After injection, the molecule targets tumor surface markers. The fluorescent dye then act as a revelator, allowing visualization of micro-tumors and radical tumor resection by the surgeon, thanks to real-time evaluation of the tumor margins.Read more